Swiss pharmaceutical company Novartis has observed in a clinical trial the superiority of its Scemblix over the current standard of care for patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukaemia after 48 weeks.
This content was published on
2 minutes
Keystone-SDA
Español
es
Novartis avanza con un fármaco contra la leucemia mieloide
The currently experimental treatment has demonstrated a significant response rate both statistically and clinically, thus meeting the two primary evaluation criteria set for the Asc4first program, assures the Basel group in a press release, without time to detail the extent of these advantages.
Scemblix (asciminib) also has a more favorable safety profile than the cocktail of imatinib, nilotinib, dasatinib and bosutinib (TKIs), generally administered to these patients.
Novartis plans to detail the results obtained at an upcoming medical conference. In the meantime, the laboratory points out that more than 60% of people with Philadelphia chromosome-positive chronic myelogenous leukaemia fail to show a molecular response to TKIs after one year and that the side effects of this type of treatment burden lead a quarter of patients to abandon treatment before five years.
The Asc4first program continues, with a new update planned when data on 96 weeks of treatment is available.
More
More
Three Swiss companies among the 100 most valuable in the world
This content was published on
Three Swiss companies have once again made it into the top 100 most valuable listed companies in the world.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Switzerland to introduce flight passenger database
This content was published on
Switzerland plans to introduce a flight passenger database to collect and process personal data in a bid to combat terrorism and serious crime.
Government plans to invest over CHF16bn in Swiss rail network
This content was published on
The federal government intends to invest CHF16.4 billion ($18.1 billion) in railway infrastructure between 2025 and 2028, CHF2 billion more than for the current period.
Swiss to vote on pension reform and biodiversity in September
This content was published on
Swiss citizens will vote on occupational pension schemes and a biodiversity initiative on September 22, the Federal Council announced on Wednesday.
Ukraine peace talks: 50 countries have confirmed participation
This content was published on
To date, 50 countries out 160 invited delegations have confirmed they will attend the Ukraine peace conference, held in central Switzerland in mid-June, according to Swiss public radio, RTS.
Federer-backed On boosts forecast after sneaker demand rises
This content was published on
Swiss footwear company On Holding AG posted strong first-quarter revenue, boosted by demand for its running shoes and new line of training apparel.
Michael Schumacher’s watches fetch CHF4 million at Swiss auction
This content was published on
Watches belonging to Formula 1 great Michael Schumacher sold for around CHF4 million ($4.41 million) at auction house Christie's in Geneva on Tuesday.
Macron will attend Swiss summit on Ukraine, says Zelensky
This content was published on
French President Emmanuel Macron will attend the peace conference on Ukraine at the Swiss Bürgenstock resort next month, according to Volodymyr Zelensky.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis withdraws patent claim on leukaemia treatment
This content was published on
The Swiss NGO Public Eye is claiming victory in the European Patent OfficeExternal link battle, but Novartis says the patent in question was only one of several it has in place on the (CAR)-T cell therapy treatment it had developed together with the University of Pennsylvania. Public Eye says the therapy costs CHF370,000 ($376,000), which…
Sandoz CEO: Switzerland could save millions on medicines
This content was published on
Sandoz chief executive Richard Saynor says Switzerland could save millions on medicine if it made greater use of generic medicine.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.